Pharmacotherapy of Paget's disease of bone

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 5, 2012, Pages 637-646

  Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alendronate; Bisphosphonates; Etidronate; Paget's disease of bone; Risedronate; Zoledronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; HYDROXYAPATITE; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ANALGESIA; BONE PAIN; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEMUR SUBTROCHANTERIC FRACTURE; FLUSHING; FOLLOW UP; HEALING; HUMAN; HYPOCALCEMIA; INJURY; OSTEOMALACIA; OSTEOPOROSIS; PAGET BONE DISEASE; QUALITY OF LIFE; REMISSION; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEITIS DEFORMANS;

EID: 84858663104     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.662486     Document Type: Review

References (59)

1. Seitz S, Priemel M, Zustin J, et al. Paget's dsease of bone: histologic analysis of 754 patients. J Bone Miner Res 2009;24:62-9
2. Renier JC, Audran M. Progression in length and width of pagetic lesions, and estimation of age at disease onset. Rev Rhum 1997;64:35-43 (Pubitemid 27099685)
3. Renier JC, Audran M. Polyostotic pagets disease - A search for lesions of different durations and for new lesions. Rev Rhum 1997;64:233-42 (Pubitemid 27223506)
4. Haddaway MJ, Davie MWJ, McCall IW, et al. Effect of age and gender on the number and distribution of sites in Paget's disease of bone. Br J Radiol 2007;80:532-6 (Pubitemid 47343081)
5. Naot D, Bava U, Matthews B, et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J Bone Miner Res 2007;22:298-309 (Pubitemid 46167800)
6. Cundy T, Bolland M. Paget disease of bone. Trends Endocrinol Metab 2008;19:246-53
7. Hamadouche M, Mathieu M, Topouchian V, et al. Transfer of Paget' s disease from one part of the skeleton to another as a result of autogenous bone-grafting - A case report. J Bone Joint Surg Am 2002;84A:2056-61 (Pubitemid 35283375)
8. Kanis JA. Pathophysiology and Treatment of Paget's Disease of Bone. Martin Dunitz; London: 1991
9. Layfield R, Hocking LJ. SQSTM1 and Paget's disease of bone. Calcif Tissue Int 2004;75:347-57 (Pubitemid 40100881)
10. Rhodes EC, Johnson-Pais TL, Singer FR, et al. Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United States. Calcif Tissue Int 2008;82:271-7 (Pubitemid 351624500)
11. Bolland MJ, Tong PC, Naot D, et al. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res 2007;22:411-15 (Pubitemid 46797124)
12. Albagha OME, Wani SE, Visconti MR. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet 2011;43:685-9
13. Friedrichs WE, Reddy SV, Bruder JM, et al. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 2002;17:145-51 (Pubitemid 33151006)
14. Matthews BG, Afzal MA, Minor PD, et al. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. J Clin Endocrinol Metab 2008;93:1398-401 (Pubitemid 351519740)
15. Kurihara N, Hiruma Y, Yamana K, et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62 (P392L) mutation to Paget's disease. Cell Metab 2011;13:23-34
16. Cundy HR, Gamble G, Wattie D, et al. Paget's disease of bone in New Zealand: Continued decline in disease severity. Calcif Tissue Int 2004;75:358-64 (Pubitemid 40100882)
17. Van Staa TP, Selby P, Leufkens HGM, et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002;17:465-71 (Pubitemid 34171761)
18. Wallace E, Wong JC, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Int Med 1995;155:1813-15
19. Eekhoff M, Van der Klift M, Kroon HM, et al. Paget's disease of bone in the Netherlands: A population-based radiological and biochemical survey - The Rotterdam Study. J Bone Miner Res 2004;19:566-70 (Pubitemid 41071216)
20. Langston AL, Campbell MK, Fraser WD, et al. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 2007;80:1-9 (Pubitemid 46095744)
21. Davie M, Davies M, Francis R, et al. Paget's disease of bone: A review of 889 patients. Bone 1999;24:11-12S
22. Barker DJP. The epidemiology of Paget' s disease of bone. Br Med Bull 1984;40:396-400
23. Altman RD, Bloch DA, Hochberg MC, et al. Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000;15:461-5 (Pubitemid 30134090)
24. Bastin S, Bird H, Gamble G, et al. Paget's disease of bone-becoming a rarity? Rheumatology 2009;48:1232-5
25. Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004;35:224-30 (Pubitemid 38789168)
26. Doyle FH, Greenberg PB, Joplin GF, et al. Radiological evidence of a dose-related response to long-term treatment of Paget's disease with human calcitonin. Br J Radiol 1974;47:1-8
27. Singer FR, Aldred JP, Neer RM, et al. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972;51:2331-8
28. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42 (Pubitemid 32112446)
29. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006;38:617-27
30. Altman RD, Johnston CC, Khairi MR, et al. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 1973;289:1379-84
31. Smith R, Russell RGG, Bishop MC, et al. Paget's disease of bone: Experience with a diphosphonate (disodium etidronate) in treatment. Q J Med 1973;42:235-56
32. De Vries HR, Bijvoet OLM. Results of prolonged treatment of Paget's disease of bone with disodiun ethane-1- hydroxy-1, 1-diphosphonate (EHDP). Neth J Med 1974;17:281-98
33. Khairi MRA, Johnston CC, Altman RD, et al. Treatment of Paget's disease of bone (osteitis deformans). JAMA 1974;28:562-7
34. Kantrowitz FG, Byrne MH, Schiller AL, et al. Clinical and biochemical effects of diphosphonates in Paget's diseasde of bone. Arthritis Rhem 1975;18:407
35. Khairi MRA, Altman RD, De Rosa GP, et al. Sodium etidronate in the treatment of Paget's disease of bone: A study of long term results. Ann Intern Med 1977;87:656-63 (Pubitemid 8262898)
36. FrijlinkWB, te Velde J, et al. Treatment of Paget's disease with (3-amino- 1-hydoxypropylidene)-1,1-bisphosphonate (APD). Lancet 1979;i:799-803 (Pubitemid 9150534)
37. Dodd GW, Ibbertson HK, Fraser TRC, et al. Radiological assessment of Paget' s disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol 1987;60:849-60 (Pubitemid 18089507)
38. Reid IR, King AR, Alexander CJ, et al. Prevention of steroid-induced osteoporosis with (3-amino-1- hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;i:143-6 (Pubitemid 18027995)
39. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate - A randomized, placebo-controlled trial. Am J Med 1996;101:341-8 (Pubitemid 26392850)
40. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget' s disease of bone. J Clin Endocrinol Metab 1996;81:961-7 (Pubitemid 26083954)
41. Cukier k, Nicholson GC, et al. Longterm follow-up of alendronate treatment in Paget's disease Presented at the International Symposium on Paget's Disease; 8 - 9 July 2009; Oxford, UK
42. Hosking DJ, Eusebio RA, Chines AA. Pagets-disease of bone - reduction of disease activity with oral risedronate. Bone 1998;22:51-5 (Pubitemid 28033653)
43. Singer FR, Clemens TL, Eusebio RA, et al. Risedronate, a highly effective oral agent in the treatment of patients with severe Pagets-disease. J Clin Endocrinol Metab 1998;83:1906-10 (Pubitemid 28496314)
44. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Pagets-disease of bone - An open label, multicenter study. J Bone Miner Res 1998;13:1032-8 (Pubitemid 28265282)
45. Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999;106:513-20 (Pubitemid 29231101)
46. Reid IR, Miller P, Lyles K, et al. omparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908 (Pubitemid 41247929)
47. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142-8 (Pubitemid 46032607)
48. Reid IR, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Paget's disease - data to 6.5 years. J Bone Miner Res 2011;26:2261-2270
49. Cornish J, Bava U, Callon KE, et al. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone 2011;49:710-16
50. Heaney RP, Armas LAG, Shary JR, et al. 25-Hydroxylation of vitamin D-3: Relation to circulating vitamin D-3 under various input conditions. Am J Clin. Nutr. 2008;87:1738-42 (Pubitemid 351872637)
51. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809 (Pubitemid 350044800)
52. Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2008;published online; doi: 10.1007/ s00256-008-0549-x
53. Kilcoyne A, Heffernan EJ. Atypical proximal femoral fractures in patients with paget disease receiving bisphosphonate therapy. Am J Roentgenol 2011;197:W196-7
54. Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget' s disease of bone. J Bone Miner Res 2009;25:20-31
55. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-pivotal fracture trial. J Bone Miner Res 2012;27:243-254
56. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Miner Res 2010;25:2256-65
57. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase II clinical trial. Bone 2008;43:222-9
58. Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26:242-51
59. Lyles KW, Siris ES, Singer FR, et al. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 2001;16:1379-87 (Pubitemid 32675190)